The estimated Net Worth of William D Young is at least $14.4 Millón dollars as of 2 January 2020. Mr. Young owns over 20,000 units of Vertex Pharmaceuticals stock worth over $13,915,104 and over the last 14 years he sold VRTX stock worth over $0. In addition, he makes $522,603 as Independent Director at Vertex Pharmaceuticals.
William has made over 2 trades of the Vertex Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of VRTX stock worth $1,442,800 on 2 January 2020.
The largest trade he's ever made was exercising 30,000 units of Vertex Pharmaceuticals stock on 30 December 2019 worth over $1,969,500. On average, William trades about 1,667 units every 0 days since 2010. As of 2 January 2020 he still owns at least 29,311 units of Vertex Pharmaceuticals stock.
You can see the complete history of Mr. Young stock trades at the bottom of the page.
William D. Young is Independent Director of Vertex Pharmaceuticals Incorporated. Mr. Young is a Senior Advisor with Blackstone Life Sciences (which acquired Clarus Ventures in 2018). Mr. Young joined Clarus Ventures, a life sciences venture capital firm, in 2010. Prior to Clarus Ventures, Mr. Young served from 1999 until June 2009 as the Chairman and Chief Executive Officer of Monogram Biosciences, Inc., a biotechnology company acquired by Laboratory Corporation of America in June 2009. From 1980 to 1999, Mr. Young was employed at Genentech, Inc. in positions of increasing responsibility, including as Chief Operating Officer from 1997 to 1999, where he was responsible for all product development, manufacturing and commercial functions. Prior to joining Genentech, Mr. Young was with Eli Lilly & Co. for 14 years. Mr. Young currently serves as the Chairman of the Board of Directors of NanoString Technologies, Inc., and as a member of the Board of Directors of Theravance BioPharma Inc. Mr. Young retired from BioMarin Pharmaceutical Inc.’s Board of Directors in November 2015 and as Biogen’s Chairman of the Board in June 2014. Mr. Young holds a B.S. in Chemical Engineering from Purdue University, an M.B.A. from Indiana University and an Honorary Doctorate in Engineering from Purdue University. Mr. Young was elected to the National Academy of Engineering in 1993 for his contributions to biotechnology.
As the Independent Director of Vertex Pharmaceuticals, the total compensation of William Young at Vertex Pharmaceuticals is $522,603. There are 18 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
William Young is 75, he's been the Independent Director of Vertex Pharmaceuticals since 2014. There are no older and 24 younger executives at Vertex Pharmaceuticals.
William's mailing address filed with the SEC is C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden y Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: